Symbols / EGRX $0.25 +0.00%
EGRX Chart
About
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 3.29M |
| Enterprise Value | 61.53M | Income | 11.95M | Sales | 257.55M |
| Book/sh | 19.25 | Cash/sh | 1.18 | Dividend Yield | — |
| Payout | 0.00% | Employees | 134 | IPO | — |
| P/E | 2.78 | Forward P/E | 0.07 | PEG | — |
| P/S | 0.01 | P/B | 0.01 | P/C | — |
| EV/EBITDA | 0.99 | EV/Sales | 0.24 | Quick Ratio | 1.51 |
| Current Ratio | 2.16 | Debt/Eq | 28.75 | LT Debt/Eq | — |
| EPS (ttm) | 0.09 | EPS next Y | 3.48 | EPS Growth | — |
| Revenue Growth | -12.80% | Earnings | 2023-08-08 07:00 | ROA | 6.63% |
| ROE | 4.88% | ROIC | — | Gross Margin | 69.84% |
| Oper. Margin | 15.94% | Profit Margin | 4.64% | Shs Outstand | 13.16M |
| Shs Float | 5.91M | Short Float | 4.19% | Short Ratio | 3.91 |
| Short Interest | — | 52W High | 3.87 | 52W Low | 0.00 |
| Beta | 1.03 | Avg Volume | 3.11K | Volume | 100.00 |
| Target Price | — | Recom | None | Prev Close | $0.25 |
| Price | $0.25 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.25
Latest analyst target
3. DCF / Fair value
$52.42
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.25
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-08-09 | down | Piper Sandler | Neutral → Underweight | $17 |
| 2020-03-02 | main | Cantor Fitzgerald | — → Neutral | $46 |
| 2019-03-22 | main | Mizuho | Neutral → Neutral | $41 |
| 2018-10-31 | down | Piper Sandler | Overweight → Neutral | $54 |
| 2018-09-21 | main | Cantor Fitzgerald | Overweight → Overweight | $80 |
| 2018-06-12 | init | Cantor Fitzgerald | — → Overweight | $81 |
| 2018-06-11 | up | Mizuho | Underperform → Neutral | — |
| 2017-01-09 | down | Mizuho | Neutral → Underperform | $64 |
| 2016-11-03 | up | Mizuho | Neutral → Buy | — |
| 2016-11-02 | main | William Blair | — → Outperform | — |
| 2016-06-20 | down | Mizuho | — → Neutral | — |
| 2015-12-09 | init | Mizuho | — → Buy | $112 |
| 2015-12-08 | init | Mizuho | — → Buy | $112 |
| 2015-08-12 | main | Piper Sandler | — → Overweight | $120 |
| 2015-06-22 | init | RBC Capital | — → Outperform | $97 |
| 2015-06-16 | main | Cantor Fitzgerald | — → Buy | $95 |
| 2015-04-15 | main | Cantor Fitzgerald | — → Buy | $65 |
| 2015-03-31 | main | Cantor Fitzgerald | — → Buy | $51 |
| 2014-08-13 | main | Cantor Fitzgerald | — → Buy | $30 |
| 2014-03-10 | init | William Blair | — → Outperform | — |
- Unaudited Q2 2025 financials available — Eagle Pharmaceuticals posts three- and six-month statements - Stock Titan Wed, 15 Oct 2025 07
- Only FDA-approved post-surgery nausea drug shifts to new owner - Stock Titan Wed, 14 Jan 2026 08
- The Truth About Eagle Pharmaceuticals: Is EGRX the Comeback Story No One Saw Coming? - AD HOC NEWS Mon, 19 Jan 2026 08
- Q1 2025 Unaudited Financials — Eagle Pharmaceuticals posts statements and investor materials available now - Stock Titan Mon, 06 Oct 2025 07
- Eagle Pharmaceuticals and Acacia Pharma Transaction - William Blair Wed, 30 Mar 2022 07
- Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis - MarketBeat Mon, 15 Jun 2015 13
- Union Square Park Capital Management's Strategic Acquisition of Eagle Pharmaceuticals Shares - Yahoo Finance ue, 08 Oct 2024 07
- Eagle Pharmaceuticals switches to BDO after Ernst & Young dismissal - Investing.com Wed, 27 Nov 2024 08
- Eagle Pharma Downgraded On 'Challenging' Hospital Environment - Investor's Business Daily Mon, 20 Jun 2016 07
- Major Cash Injection: Eagle Pharma Lands $69M Through Strategic Royalty Sale - Stock Titan Mon, 31 Mar 2025 07
- 8 Stocks to Buy for a Great 2016 - Money/ US News hu, 06 Jul 2017 12
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.27 |
| NormalizedEBITDA | 77.50M | 847.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | 35.64M | -8.63M |
| ReconciledDepreciation | 12.02M | 3.76M |
| ReconciledCostOfRevenue | 94.94M | 42.18M |
| EBITDA | 77.50M | 847.00K |
| EBIT | 65.48M | -2.91M |
| NetInterestIncome | -3.77M | -1.07M |
| InterestExpense | 4.04M | 1.64M |
| InterestIncome | 271.00K | 560.00K |
| NormalizedIncome | 35.64M | -8.63M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 35.64M | -8.63M |
| TotalExpenses | 235.65M | 168.78M |
| TotalOperatingIncomeAsReported | 80.96M | 2.77M |
| DilutedAverageShares | 13.07M | 13.05M |
| BasicAverageShares | 12.93M | 13.05M |
| DilutedEPS | 2.73 | -0.66 |
| BasicEPS | 2.76 | -0.66 |
| DilutedNIAvailtoComStockholders | 35.64M | -8.63M |
| NetIncomeCommonStockholders | 35.64M | -8.63M |
| NetIncome | 35.64M | -8.63M |
| NetIncomeIncludingNoncontrollingInterests | 35.64M | -8.63M |
| NetIncomeContinuousOperations | 35.64M | -8.63M |
| TaxProvision | 25.79M | 4.08M |
| PretaxIncome | 61.43M | -4.55M |
| OtherIncomeExpense | -15.75M | -6.24M |
| OtherNonOperatingIncomeExpenses | -15.75M | -6.24M |
| NetNonOperatingInterestIncomeExpense | -3.77M | -1.07M |
| InterestExpenseNonOperating | 4.04M | 1.64M |
| InterestIncomeNonOperating | 271.00K | 560.00K |
| OperatingIncome | 80.96M | 2.77M |
| OperatingExpense | 140.71M | 126.60M |
| ResearchAndDevelopment | 34.09M | 51.27M |
| SellingGeneralAndAdministration | 106.63M | 75.32M |
| GrossProfit | 221.67M | 129.37M |
| CostOfRevenue | 94.94M | 42.18M |
| TotalRevenue | 316.61M | 171.55M |
| OperatingRevenue | 316.61M | 171.55M |
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| TreasurySharesNumber | 4.55M | 4.11M |
| OrdinarySharesNumber | 13.02M | 12.79M |
| ShareIssued | 17.57M | 16.90M |
| NetDebt | 7.14M | |
| TotalDebt | 64.00M | 26.92M |
| TangibleBookValue | 70.20M | 126.04M |
| InvestedCapital | 296.03M | 202.06M |
| WorkingCapital | 77.67M | 98.23M |
| NetTangibleAssets | 70.20M | 126.04M |
| CapitalLeaseObligations | 1.53M | 1.31M |
| CommonStockEquity | 233.56M | 176.45M |
| TotalCapitalization | 289.78M | 176.45M |
| TotalEquityGrossMinorityInterest | 233.56M | 176.45M |
| StockholdersEquity | 233.56M | 176.45M |
| GainsLossesNotAffectingRetainedEarnings | -1.11M | -94.00K |
| OtherEquityAdjustments | -1.11M | -94.00K |
| TreasuryStock | 243.12M | 225.11M |
| RetainedEarnings | 111.50M | 75.86M |
| AdditionalPaidInCapital | 366.26M | 325.78M |
| CapitalStock | 18.00K | 17.00K |
| CommonStock | 18.00K | 17.00K |
| PreferredStock | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 172.60M | 77.28M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 61.51M | 2.90M |
| OtherNonCurrentLiabilities | 5.30M | 2.90M |
| LongTermDebtAndCapitalLeaseObligation | 56.22M | 2.90M |
| LongTermCapitalLeaseObligation | 3.79M | 2.90M |
| LongTermDebt | 56.22M | |
| CurrentLiabilities | 111.09M | 74.38M |
| OtherCurrentLiabilities | 10.84M | 6.18M |
| CurrentDebtAndCapitalLeaseObligation | 7.78M | 26.92M |
| CurrentCapitalLeaseObligation | 1.53M | 1.31M |
| CurrentDebt | 6.25M | 25.61M |
| OtherCurrentBorrowings | 6.25M | 25.61M |
| PayablesAndAccruedExpenses | 92.46M | 41.28M |
| CurrentAccruedExpenses | 46.08M | 19.77M |
| Payables | 46.38M | 21.52M |
| OtherPayable | 22.20M | 5.08M |
| TotalTaxPayable | 5.18M | 0.00 |
| IncomeTaxPayable | 5.18M | 0.00 |
| AccountsPayable | 18.99M | 16.43M |
| TotalAssets | 406.16M | 253.73M |
| TotalNonCurrentAssets | 217.41M | 81.13M |
| OtherNonCurrentAssets | 25.73M | 10.28M |
| NonCurrentDeferredAssets | 27.15M | 18.80M |
| NonCurrentDeferredTaxesAssets | 27.15M | 18.80M |
| GoodwillAndOtherIntangibleAssets | 163.36M | 50.41M |
| OtherIntangibleAssets | 118.33M | 10.67M |
| Goodwill | 45.03M | 39.74M |
| NetPPE | 1.17M | 1.64M |
| AccumulatedDepreciation | -6.60M | -5.96M |
| GrossPPE | 7.77M | 7.59M |
| Leases | 1.16M | 1.16M |
| OtherProperties | 4.01M | 3.83M |
| MachineryFurnitureEquipment | 2.60M | 2.60M |
| Properties | 0.00 | 0.00 |
| CurrentAssets | 188.75M | 172.61M |
| OtherCurrentAssets | 3.26M | 1.40M |
| PrepaidAssets | 8.94M | 4.83M |
| Inventory | 47.79M | 21.91M |
| FinishedGoods | 21.38M | 4.92M |
| WorkInProcess | 14.06M | 9.67M |
| RawMaterials | 12.35M | 7.32M |
| Receivables | 73.44M | 46.81M |
| OtherReceivables | 1.00M | 347.00K |
| NotesReceivable | 0.00 | 5.31M |
| AccountsReceivable | 72.44M | 41.15M |
| CashCashEquivalentsAndShortTermInvestments | 55.32M | 97.66M |
| CashAndCashEquivalents | 55.32M | 97.66M |
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| FreeCashFlow | 50.52M | 27.90M |
| RepurchaseOfCapitalStock | -18.00M | -21.21M |
| RepaymentOfDebt | -67.24M | -8.00M |
| IssuanceOfDebt | 80.00M | 0.00 |
| CapitalExpenditure | -178.00K | -323.00K |
| InterestPaidSupplementalData | 1.73M | 1.20M |
| IncomeTaxPaidSupplementalData | 28.41M | 10.01M |
| EndCashPosition | 55.32M | 97.66M |
| BeginningCashPosition | 97.66M | 103.16M |
| ChangesInCash | -42.34M | -5.50M |
| FinancingCashFlow | -6.21M | -28.39M |
| CashFlowFromContinuingFinancingActivities | -6.21M | -28.39M |
| NetOtherFinancingCharges | -2.72M | -1.58M |
| ProceedsFromStockOptionExercised | 1.75M | 2.40M |
| NetCommonStockIssuance | -18.00M | -21.21M |
| CommonStockPayments | -18.00M | -21.21M |
| NetIssuancePaymentsOfDebt | 12.76M | -8.00M |
| NetShortTermDebtIssuance | 15.00M | 0.00 |
| ShortTermDebtPayments | -15.00M | 0.00 |
| ShortTermDebtIssuance | 30.00M | 0.00 |
| NetLongTermDebtIssuance | -2.24M | -8.00M |
| LongTermDebtPayments | -52.24M | -8.00M |
| LongTermDebtIssuance | 50.00M | 0.00 |
| InvestingCashFlow | -86.83M | -5.32M |
| CashFlowFromContinuingInvestingActivities | -86.83M | -5.32M |
| NetOtherInvestingChanges | -5.00M | |
| NetInvestmentPurchaseAndSale | -12.50M | 0.00 |
| PurchaseOfInvestment | -12.50M | 0.00 |
| NetBusinessPurchaseAndSale | -74.15M | 0.00 |
| PurchaseOfBusiness | -74.15M | 0.00 |
| NetPPEPurchaseAndSale | -178.00K | -323.00K |
| PurchaseOfPPE | -178.00K | -323.00K |
| OperatingCashFlow | 50.70M | 28.22M |
| CashFlowFromContinuingOperatingActivities | 50.70M | 28.22M |
| ChangeInWorkingCapital | -16.40M | 9.54M |
| ChangeInOtherWorkingCapital | -18.62M | -1.32M |
| ChangeInPayablesAndAccruedExpense | 46.55M | 17.93M |
| ChangeInAccruedExpense | 43.58M | 7.77M |
| ChangeInPayable | 2.97M | 10.16M |
| ChangeInAccountPayable | 2.97M | 10.16M |
| ChangeInPrepaidAssets | -5.16M | -2.77M |
| ChangeInInventory | -8.34M | -13.83M |
| ChangeInReceivables | -30.83M | 9.53M |
| ChangesInAccountReceivables | -30.83M | 9.53M |
| OtherNonCashItems | 1.45M | 2.13M |
| StockBasedCompensation | 16.45M | 19.55M |
| DeferredTax | -8.32M | -3.62M |
| DeferredIncomeTax | -8.32M | -3.62M |
| DepreciationAmortizationDepletion | 12.02M | 3.76M |
| DepreciationAndAmortization | 12.02M | 3.76M |
| AmortizationCashFlow | 11.38M | 3.00M |
| AmortizationOfIntangibles | 11.38M | 3.00M |
| Depreciation | 646.00K | 764.00K |
| OperatingGainsLosses | 9.86M | 5.48M |
| EarningsLossesFromEquityInvestments | 4.46M | 6.17M |
| GainLossOnInvestmentSecurities | 962.00K | -686.00K |
| NetIncomeFromContinuingOperations | 35.64M | -8.63M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for EGRX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|